Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Alzheimer's
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Alzheimer's
    TopAbstracts in Alzheimer's 06/25/2009 - (DGNews)
    Depression May Increase Risk of Alzheimer's in People With Mild Cognitive Impairment - (DGNews)
    Self administered cognitive screening test (TYM) for detection of Alzheimer's disease: cross sectional study - (BMJ)
    TopAbstracts in Alzheimer's 06/11/2009 - (DGNews)
    Cognitive Impairment Increases Risk of Death in Older Adults, Regardless of Race - (DGNews)

    News archive

     Recent webcasts/CME - Alzheimer's
    • Dementia in Hispanic Americans: The Reasons Behind the Risk
    • Modifiable Risk Factors Underlie Higher Dementia Rates in African Americans
    • The Dementia Caregiver-A Primary Care Approach
      Medical Care of the Patient with Dementia
      Creativity and Dementia: Emerging Diagnostic and Treatment Methods for Alzheimer's Disease

      Webcasts/CME archive

       Recent cases - Alzheimer's
        Rapid Cognitive Improvement in Alzheimer's Disease Following Perispinal Etanercept Administration
        Advances in the Pharmacotherapy of Alzheimer's Disease
        Distinguishing Alzheimer's From Parkinson's
        Does He Have Alzheimer's Disease?

        Cases archive
          




        my personal edition > alzheimer's > news
        divider

          E-Mail this DGNews to a colleague

        DGNews


        FDA Approves Orally Disintegrating Tablet Formulation of Aricept (Donepezil) for Treatment of Mild to Moderate Alzheimer's Disease

        RIDGEFIELD PARK, NJ -- October 21, 2004 -- Eisai Global Clinical Development announced today that the U.S. Food and Drug Administration has approved AriceptŪ ODT™ (donepezil HCl) Orally Disintegrating Tablets, the first such medication approved by the FDA to treat the symptoms of mild to moderate Alzheimer's disease.

        Aricept ODT will be available in the U.S. in 5 mg and 10 mg tablets in blister packaging and will provide the same dosage strength of drug as Aricept tablets. It will be available in the second quarter of 2005 and will be co-promoted by Eisai Inc. and Pfizer Inc. A similar dosage form was approved for use in Japan in February 2004. Additionally, an application was filed with the regulatory authorities in Europe in December 2003. Eisai developed the technology for Aricept ODT.

        The new dosage form was designed to make administration easier for patients. Studies have shown that patients with Alzheimer's disease may develop difficulty with swallowing.

        "Aricept ODT demonstrates Eisai and Pfizer's commitment to scientific innovations that may improve the lives of Alzheimer's patients and their caregivers," said Mindell Seidlin, M.D., president, Eisai Global Clinical Development.

        Information About Aricept (donepezil HCl tablets) Treatment in Alzheimer's Disease

        While there is no cure for Alzheimer's disease, medical treatments are available to manage symptoms of the disease. Once-a-day prescription Aricept is indicated for mild to moderate Alzheimer's disease. Aricept is co-promoted in the United States by Eisai Inc. and Pfizer Inc.

        Aricept is well tolerated but may not be for everyone. People at risk for stomach ulcers or who take certain other medicines should tell their doctors because serious stomach problems, such as bleeding, may get worse.

        Some people may have nausea, diarrhea, not sleep well or vomit. Some people may have muscle cramps, feel very tired, or may not want to eat. In studies, these side effects were usually mild and went away over time. Some people who take Aricept may experience fainting.

        For full prescribing information on Aricept, please visit http://www.aricept.com.


        SOURCE: Eisai Inc.



        E-Mail this DGNews to a colleague   To print, use this version






        All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send